WinstonWınston
Back
Stock

Cresco Labs

CRLBF
27
Drug Manufacturers - Specialty & Generic · Healthcare
Price
$0.78
+0.04 (+5.23%)
Market Cap
$276.3M
Exchange
Other OTC
Winston Score
27
Winston is worried
Below-average fundamentals — multiple weak pillars.
Data as of Sep 6, 2026 · filings through Jun 30, 2026

§How the score breaks down

Quality
Mixed
Growth
Weak
Cash Flow
Weak
Stability
Mixed
Valuation
Data not available
Track this stock — start free trial

Share count rising — dilution

+29.8% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 262.3M (2021) → 340.5M (2025)

§Winston Score History

The full picture

Cresco Labs is one of the largest cannabis companies in the United States. It grows, processes, and sells marijuana products for both medical and recreational use. The company operates dispensaries under the Sunnyside brand and sells wholesale products to other retailers across multiple states.

Cresco makes money by selling cannabis flower, edibles, vapes, and other products through its own retail stores and through wholesale distribution to third-party dispensaries. It operates in about a dozen U.S. states, with a strong presence in Illinois, Pennsylvania, and Ohio. Its wholesale distribution network is one of the largest among U.S. cannabis operators, giving it broader retail reach than many competitors. The biggest growth opportunity is continued state-level legalization, but the company faces significant risks from ongoing federal prohibition, limited access to traditional banking, and heavy debt loads common across the cannabis industry.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+5.9% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

+208.5% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$0/ year

0.0% of revenue

Below sector average (18%)

Research and development spending

Insider Activity

2.4%ownership

Relatively low insider ownership

Cash Position

Cash flow positive

$33M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Company generates more cash than it spends — no dilution risk from fundraising

Growth context

Cresco Labs is growing revenue at 6% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
50.2%
Healthy — 50.2% gross margin
Profit after running costs
Operating Margin
7.7%
Modest — 7.7% operating margin
Return on the money invested
ROCE
8.1%
Below par — 8.1% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
-4.5%
Shrinking sales (-4.5% YoY)
Profit growth
EPS YoY
N/A
Data not available
How steady the profit is
EPS Consistency
4/8 quarters
Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
N/A
Data not available
Spare cash per sale
FCF Margin
1.6%
Thin free cash flow (1.6%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
1.19
Elevated debt (1.19)
Covers its interest
Interest Cover
1.06x
Dangerous — barely covers interest (1.1x)

Interest coverage between 1 and 3. Profits cover interest, but with little room to spare.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
N/M
Negative earnings — P/E not meaningful
Cheaper or dearer next year
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial